Sana Biotechnology (SANA) Other Non-Current Liabilities (2020 - 2026)

Sana Biotechnology's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 3.83% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (up 3.83% YoY), while the FY2025 annual figure was $83.5 million, up 743.96% from the prior year.
• Other Non-Current Liabilities came in at $9.8 million for Q1 2026 at Sana Biotechnology, down from $83.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $110.5 million in Q2 2023 to a low of $7.3 million in Q2 2024.
• A 5-year average of $66.2 million and a median of $81.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities plunged 93.39% in 2024 and soared 802.49% in 2025, its largest moves.
• Sana Biotechnology's Other Non-Current Liabilities stood at $95.0 million in 2022, then rose by 15.33% to $109.6 million in 2023, then tumbled by 90.97% to $9.9 million in 2024, then jumped by 743.96% to $83.5 million in 2025, then tumbled by 88.26% to $9.8 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $9.8 million, $83.5 million, and $63.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison